We carry out research on early diagnostics, therapeutics, and preventive approaches to Alzheimer’s disease. The formation of pathological changes in Alzheimer’s disease, such as amyloid β aggregates and tau pathology begins decades before cognitive decline appears, which may trigger the onset of Alzheimer’s disease. It also may be possible to stop the onset of Alzheimer’s disease if a person potential to Alzheimer’s disease can be found and treated at the preclinical stage. We are trying a variety of approaches to conquer Alzheimer’s disease with a flexible mindset. We have also shown that Shiga-Y6 has beneficial effects on diabetes via elevation of TXNIP using a mouse model.